Home Applications 206426 Application 206426
Type NDA
Sponsor BIOCRYST Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 RAPIVAB PERAMIVIR SOLUTION;INTRAVENOUS 200MG/20ML (10MG/ML) Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N206426-001 RAPIVAB PERAMIVIR 200MG/20ML (10MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2014-12-19
Orange Book patents# Current patent rows page 1 of 1 · 5 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N206426-001 10391075 2027-02-12 U-2622 2019-09-25 N206426-001 10391075 2027-02-12 U-3069 2019-09-25 N206426-001 8778997 2027-05-07 U-1627 2015-01-13 N206426-001 8778997 2027-05-07 U-2622 2015-01-13 N206426-001 8778997 2027-05-07 U-3069 2015-01-13
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 44 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-10-28 04:53 UTC 2022-10 N206426-001 RAPIVAB 200MG/20ML (10MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2014-12-19 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N206426-001 RAPIVAB 200MG/20ML (10MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2014-12-19 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N206426-001 RAPIVAB 200MG/20ML (10MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2014-12-19 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N206426-001 RAPIVAB 200MG/20ML (10MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2014-12-19 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 6 · 230 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-10-15 13:18:30 2026-09 N206426-001 10391075 2027-02-12 U-2622 2019-09-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N206426-001 10391075 2027-02-12 U-3069 2019-09-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N206426-001 8778997 2027-05-07 U-2622 2015-01-13 c2088c7a36db…2026-10-15 13:18:30 2026-09 N206426-001 8778997 2027-05-07 U-1627 2015-01-13 c2088c7a36db…2026-10-15 13:18:30 2026-09 N206426-001 8778997 2027-05-07 U-3069 2015-01-13 c2088c7a36db…2026-09-14 22:38:34 2026-08 N206426-001 10391075 2027-02-12 U-2622 2019-09-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N206426-001 10391075 2027-02-12 U-3069 2019-09-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N206426-001 8778997 2027-05-07 U-2622 2015-01-13 84e616aacf4f…2026-09-14 22:38:34 2026-08 N206426-001 8778997 2027-05-07 U-1627 2015-01-13 84e616aacf4f…2026-09-14 22:38:34 2026-08 N206426-001 8778997 2027-05-07 U-3069 2015-01-13 84e616aacf4f…2026-08-18 06:07:40 2026-07 N206426-001 10391075 2027-02-12 U-2622 2019-09-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N206426-001 10391075 2027-02-12 U-3069 2019-09-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N206426-001 8778997 2027-05-07 U-2622 2015-01-13 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N206426-001 8778997 2027-05-07 U-1627 2015-01-13 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N206426-001 8778997 2027-05-07 U-3069 2015-01-13 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N206426-001 10391075 2027-02-12 U-2622 2019-09-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N206426-001 10391075 2027-02-12 U-3069 2019-09-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N206426-001 8778997 2027-05-07 U-2622 2015-01-13 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N206426-001 8778997 2027-05-07 U-1627 2015-01-13 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N206426-001 8778997 2027-05-07 U-3069 2015-01-13 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N206426-001 10391075 2027-02-12 U-2622 2019-09-25 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N206426-001 10391075 2027-02-12 U-3069 2019-09-25 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N206426-001 8778997 2027-05-07 U-2622 2015-01-13 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N206426-001 8778997 2027-05-07 U-1627 2015-01-13 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N206426-001 8778997 2027-05-07 U-3069 2015-01-13 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N206426-001 10391075 2027-02-12 U-2622 2019-09-25 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N206426-001 10391075 2027-02-12 U-3069 2019-09-25 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N206426-001 8778997 2027-05-07 U-2622 2015-01-13 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N206426-001 8778997 2027-05-07 U-1627 2015-01-13 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N206426-001 8778997 2027-05-07 U-3069 2015-01-13 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N206426-001 10391075 2027-02-12 U-2622 2019-09-25 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N206426-001 10391075 2027-02-12 U-3069 2019-09-25 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N206426-001 8778997 2027-05-07 U-2622 2015-01-13 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N206426-001 8778997 2027-05-07 U-1627 2015-01-13 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N206426-001 8778997 2027-05-07 U-3069 2015-01-13 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N206426-001 10391075 2027-02-12 U-2622 2019-09-25 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N206426-001 10391075 2027-02-12 U-3069 2019-09-25 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N206426-001 8778997 2027-05-07 U-2622 2015-01-13 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N206426-001 8778997 2027-05-07 U-1627 2015-01-13 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N206426-001 8778997 2027-05-07 U-3069 2015-01-13 b8a1b40f171c…
Observed Orange Book exclusivity history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 5 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 61364-181 Rapivab peramivir Seqirus USA Inc. NDA Current 61364-181 Rapivab peramivir Seqirus USA Inc. NDA Current 72769-181 Rapivab peramivir BioCryst Pharmaceuticals, Inc. NDA Current 72769-181 Rapivab peramivir BioCryst Pharmaceuticals, Inc. NDA Current 72769-181 Rapivab peramivir BioCryst Pharmaceuticals, Inc. NDA Current